PubMed · 1994 · 124 citations · 0 references
MedicinePharmacologyPharmacotherapyBehavioral PharmacologyNeuropharmacologyPsychopharmacologyBehavior TherapyDrug DependenceNaloxone TherapyOpioid AnalgesicsOpioid PharmacologyOpioid Use DisorderAntagonist ActivityConcomitant Medication EffectsMedication Adverse EffectsNaloxone PharmacologyNaltrexone TreatmentOpioid Antagonist TherapyResponse FormSelf-injurious Behavior Assessment
The opioid antagonist naltrexone was administered to 8 adults with severe or profound mental retardation and extensive histories of self-injurious behavior. Five-minute behavioral samples were observed randomly out of every hour from 8 a.m. through 3 p.m., Monday through Friday, for four 2-week phases (baseline, placebo, 50 mg, and 100 mg). During naltrexone administration, there were fewer days with frequent head-banging and self-biting, whereas there were more days on which blows to the head or self-biting were infrequent. Self-injurious participants slept 1.38 hours less per night during baseline, which was unaffected by naltrexone.